Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRAF | P15056 | 2/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.54 |
| ▸ | NPC1 | O15118 | 3/20 | 0.54 |
| ▸ | RAB9A | P51151 | 3/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.54 |
| ▸ | MAPT | P10636 | 6/20 | 0.52 |
| ▸ | TP53 | P04637 | 5/20 | 0.52 |
| ▸ | LMNA | P02545 | 2/20 | 0.52 |
| ▸ | POLB | P06746 | 1/20 | 0.52 |
| ▸ | HPGD | P15428 | 2/20 | 0.51 |
| ▸ | CDC25B | P30305 | 3/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.47 |
| ▸ | THRB | P10828 | 1/20 | 0.47 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.46 |
| ▸ | SYK | P43405 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6578900 | 0.89 | MAPK1 (0.51) | BRAFSMN1; SMN2NPC1RAB9AKDM4E | |
| SCHEMBL4893816 | 0.85 | SMN1; SMN2 (0.59) | BRAFSMN1; SMN2NPC1RAB9AKDM4E | |
| SCHEMBL7108109 | 0.84 | TOP2A (0.55) | NPC1RAB9AKDM4EMEN1ALDH1A1 | |
| SCHEMBL7104854 | 0.83 | SMN1; SMN2 (0.56) | BRAFSMN1; SMN2NPC1RAB9AKDM4E | |
| SCHEMBL12651577 | 0.80 | SMN1; SMN2 (0.59) | BRAFSMN1; SMN2NPC1RAB9AKDM4E | |
| SCHEMBL22866110 | 0.80 | SMN1; SMN2 (0.59) | BRAFSMN1; SMN2NPC1RAB9AKDM4E | |
| SCHEMBL5840336 | 0.80 | MAPT (0.43) | SMN1; SMN2KDM4EMAPTTP53LMNA | |
| SCHEMBL4889926 | 0.79 | MAPKAPK2 (0.55) | BRAFSMN1; SMN2NPC1RAB9AKDM4E | |
| SCHEMBL4889912 | 0.79 | MAPKAPK2 (0.55) | BRAFSMN1; SMN2NPC1RAB9AKDM4E | |
| SCHEMBL4894962 | 0.78 | BRAF (0.54) | BRAFSMN1; SMN2NPC1RAB9AKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080090849-A1 | NOVEL PURINE DERIVATIVES, PREPARATION METHOD AND USE AS MEDICINES | AVENTIS PHARMA S.A. (FR) | 2008-04-17 | — | — | US | disclosed |
| US-7041824-B2 | Purine derivatives, preparation method and use as medicines | AVENTIS PHARMA S.A. (FR) | 2006-05-09 | — | — | US | disclosed |
| US-20060074095-A1 | Novel purine derivatives, preparation method and use as medicines | AVENTIS PHARMA S.A. (FR) | 2006-04-06 | — | — | US | disclosed |
| US-20040063732-A1 | Novel purine derivatives, preparation method and use as medicines | AVENTIS PHARMA S.A. (FR) | 2004-04-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040063732-A1 | Novel purine derivatives, preparation method and use as medicines | CDK1, CDK6, PNP | BRAF 330/4885SMN1; SMN2 3675/4885NPC1 1938/4885 |
| US-20080090849-A1 | NOVEL PURINE DERIVATIVES, PREPARATION METHOD AND USE AS MEDICINES | CDK1, CDK6, PNP | BRAF 243/4885SMN1; SMN2 3466/4885NPC1 2368/4885 |
| US-20060074095-A1 | Novel purine derivatives, preparation method and use as medicines | CDK1, CDK6, PNP | BRAF 315/4885SMN1; SMN2 3731/4885NPC1 2301/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.